Remove Biopharma Remove Physicians Remove Prescription Remove Sales
article thumbnail

Veradigm® Digital Health Media Works to Message the Right Physicians at the Right Time

PM360

As pharma reps’ access to physicians continues to decline, this case study examines the effectiveness of reaching physicians through other means—the EHR. Today’s physicians struggle to balance the increasing demands of patient loads, electronic health record (EHR) systems, and time spent on administrative tasks. THE CHALLENGE.

article thumbnail

Five points on CMS’s first ten picks for price negotiations

Clarivate

While more expensive than type 2 diabetes drugs, blood thinners follow a similar pattern of high prescription volumes. In both cases, a shift in formulary placement could lower prescription volumes and reduce member utilization. With 27.5% exclusions exist for orphan drug designation and biosimilar competition ).

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Five ways COVID-19 has changed healthcare provision and what it means for pharmas

Clarivate

2021 surveys of patients and physicians in the United States conducted by Clarivate show that: Much of care delivery has gone virtual. Three in five physicians in the United States (60%) report having conducted virtual consultations, as do 35% of patients. physicians; Source: Clarivate, Taking the Pulse(R) U.S.

Pharma 52
article thumbnail

Powering pharma’s commercial teams with market access insights

pharmaphorum

Market access is influencing drug development and commercial launch strategy more than ever before, with 85% of prescription drugs in the United States reimbursed through managed care plans.

article thumbnail

The AMJEVITA impact: Innovative U.S. biosimilar pricing models

Clarivate

biologics market and reduce prescription drug costs. and European physicians across six specialties, and global pipeline analysis curated by experts to provide insights into the evolving landscape. By end of year, as many as ten adalimumab biosimilars could be on the U.S. In 2022, it made its manufacturer, AbbVie, $21.2bn.

article thumbnail

Accelerating HCP engagement in Singapore using customer reference data

Veeva

There are big opportunities to increase efficiencies and sales productivity, despite Singapore being a relatively smaller market. Veeva OpenData supports users to: Increase sales productivity, speed and business efficiency. 100% said they rely on their sales reps to make changes to HCP data. Streamline compliance.

Sales 52
article thumbnail

Bringing Therapies from Bench to Bedside: Navigating Challenges in the Last Mile

Clarify Health

Performing well requires careful coordination across several functions to ensure favorable market access, differentiated product positioning, and appropriate sales force deployment. Customer conversion and product uptake have largely depended upon live interactions between treating physicians and biopharma representatives (e.g.,